Home Cart Sign in  
Chemical Structure| 222638-67-7 Chemical Structure| 222638-67-7

Structure of BEC·HCl
CAS No.: 222638-67-7

Chemical Structure| 222638-67-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BEC HCl is a competitive arginase inhibitor with Ki of 0.31 μM and 0.4-0.6 μM for Arginase II and rat Arginase I respectively.

Synonyms: BEC (hydrochloride); BEC hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BEC·HCl

CAS No. :222638-67-7
Formula : C5H13BClNO4S
M.W : 229.49
SMILES Code : O=C(O)[C@@H](N)CSCCB(O)O.[H]Cl
Synonyms :
BEC (hydrochloride); BEC hydrochloride
MDL No. :MFCD03453539
InChI Key :GHPYJLCQYMAXGG-WCCKRBBISA-N
Pubchem ID :91826515

Safety of BEC·HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MAF cells 500 μM 48 h To evaluate the inhibitory effect of BEC on arginase activity in MAF cells. Results showed that BEC inhibited arginase activity in MAF cells. PMC7581550
Bovine retinal endothelial cells 10 μM 24 h Under high glucose conditions, BEC treatment reversed the decrease in NO release, indicating that arginase inhibition restores NO bioavailability. PMC3699717
peritoneal cells 90 μM 48 h To evaluate the effect of BEC on CD3ζ re-expression, results showed that BEC could restore CD3ζ expression PMC7006169

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Diabetic mouse model In vitro incubation 50 μM 30 minutes BEC significantly enhanced endothelium-dependent and nitrergic relaxation responses in the corpus cavernosum of diabetic mice. PMC3117078
BALB/c mice Staphylococcus aureus bloodstream infection model Intraperitoneal injection 50 mg/kg Once daily for 14 days BEC enhanced NO production by inhibiting arginase activity, thereby protecting mice from Staphylococcus aureus infection PMC7399636
Zucker rats Obese Zucker rat model Intraperitoneal injection 55.6μg/hour Continuous for 6 days BEC improves endothelial function and reduces blood pressure in obese Zucker rats by inhibiting arginase activity. PMC4310823
Rat STZ-induced diabetic rats Ex vivo pretreatment 100 μM 45 minutes BEC pretreatment partially restored the endothelial-dependent vasodilation of the central retinal arteries in STZ-induced diabetic rats PMC3565067
BALB/c mice Sub-acute and chronic models of allergic airways inflammation Nebulized administration 40 μg/g Single dose, 15 minutes before pulmonary function testing BEC significantly attenuated the CAP+O3-induced increase in AHR, completely reversing the exacerbation of symptoms in OVA/OVA mice PMC3037317

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.36mL

0.87mL

0.44mL

21.79mL

4.36mL

2.18mL

43.57mL

8.71mL

4.36mL

References

 

Historical Records

Categories